October 14, 2019 03:49 PM IST Net Sales are expected to increase by 17.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 3,475.2 crore, according to Emkay.
July 12, 2019 04:33 PM IST Net Sales are expected to increase by 13.9 percent Y-o-Y (down 11.7 percent Q-o-Q) to Rs. 3,296.1 crore, according to Prabhudas Lilladher.
April 12, 2019 12:52 PM IST Net Sales are expected to decrease by 3.6 percent Y-o-Y (down 12.4 percent Q-o-Q) to Rs. 3,134.8 crore, according to Prabhudas Lilladher.
January 18, 2019 01:53 PM IST Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.
January 11, 2019 05:28 PM IST Net Sales are expected to decrease by 1.1 percent Y-o-Y (up 8.8 percent Q-o-Q) to Rs. 3,222.2 crore, according to ICICI Direct.
January 04, 2019 10:45 AM IST For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
October 17, 2018 05:55 PM IST Net Sales are expected to decrease by 5.2 percent Y-o-Y (up 5.9 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.
October 16, 2018 06:57 PM IST Net Sales are expected to decrease by 4.4 percent Y-o-Y (up 8.1 percent Q-o-Q) to Rs. 3,093 crore, according to Sharekhan.
October 12, 2018 04:30 PM IST Net Sales are expected to decrease by 7.6 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs. 2,986.6 crore, according to ICICI Direct.
July 12, 2018 09:42 PM IST "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities
May 09, 2018 08:46 AM IST Global brokerage houses have upgraded a few stocks, highlighting robust Q4 FY18 results. Moneycontrol takes a look at six such stocks which have seen a ratings upgrade
April 20, 2018 12:52 PM IST Net Sales are expected to increase by 24 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs. 3,070 crore, according to HDFC Securities.
April 16, 2018 06:01 PM IST Net Sales are expected to increase by 27.7 percent Y-o-Y (down 2.9 percent Q-o-Q) to Rs. 3,163.5 crore, according to Edelweiss.
April 12, 2018 05:53 PM IST Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
January 18, 2018 08:36 AM IST As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
January 11, 2018 04:06 PM IST The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.
April 17, 2017 01:13 PM IST Net Sales are expected to increase by 5.8 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 2434.2 crore, according to ICICI Securities. Cadila to report net profit at 309.7 crore up 19.5% quarter-on-quarter.
April 17, 2017 01:13 PM IST Net Sales are expected to increase by 5.8 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 2434.2 crore, according to ICICI Securities. Cadila to report net profit at 309.7 crore up 19.5% quarter-on-quarter.
January 14, 2017 02:22 PM IST Net Sales are expected to increase by 7.1 percent Q-o-Q (up 4.9 percent Y-o-Y) to Rs 2535.1 crore, according to ICICI Securities.
January 13, 2017 12:29 PM IST Net Sales are expected to increase by 7.5 percent Q-o-Q (up 7.3 percent Y-o-Y) to Rs 2512.6 crore, according to KR Choksey.
October 26, 2016 10:42 AM IST Pharma company Cadila Healthcare is expected to report a 2.3 percent growth in second quarter profit at Rs 399.83 crore and 0.7 percent rise in revenue at Rs 2,477.2 crore on yearly basis, according to average of estimates of analysts polled by CNBC-TV18.
July 16, 2016 01:15 PM IST Sales are expected to increase by 0.2 percent Q-o-Q (down 1.9 percent Y-o-Y) to Rs 2453.8 crore, according to Religare Research.
July 14, 2016 06:07 PM IST Net Sales are expected to increase by 3.4 percent Q-o-Q (up 4.3 percent Y-o-Y) to Rs 2532.4 crore, according to Edelweiss
May 13, 2016 09:30 AM IST During the quarter, EBITDA may increase 11 percent to Rs 551 crore compared to Rs 496 crore while operating profit margin may stand at 22 percent from 21.7 percent year-on-year.
February 04, 2016 04:33 PM IST Revenue growth is likely to be led by 12-14 percent Y-o-Y growth in US formulations while sequential US growth may remain flat due to no US launch during the quarter.
